AI-assisted heart tracing tested to speed up diagnosis of blocked heart arteries
Tests an AI tool reading heart tracings in adults with suspected acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
Key facts
- Where
- Lugano, SwitzerlandSee the site
Where in Switzerland
- Cardiocentro Ticino InstituteLugano, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cardiocentro Ticino
- Trial code
- NCT07077057
- Record updated
- 5 May 2026
- Original description
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.Read full original descriptionShow less
Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.
The main questions it aims to answer are:
1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention? 2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels?
Researchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.
Participants will:
1. Present with symptoms suggestive of ACS but without clear STEMI criteria 2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation 3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels
Inclusion: Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness; Age: Patients aged 18 years or older; Informed Consent: Patients able to provide informed consent.
Exclusion: Symptoms onset>24 hrs prior to clinical presentation; Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians; Pregnancy or Lactation; Legally incompetent to provide informed consent.